ImmunoVaccine Inc. (IMV.V)
-TSXV 0.23 
0.01(4.55%) 3:14PM EDT
| Prev Close: | 0.22 |
|---|
| Open: | 0.24 |
|---|
| Bid: | 0.23 |
|---|
| Ask: | 0.24 |
|---|
| 1y Target Est: | 0.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.22 - 0.24 |
|---|
| 52wk Range: | 0.20 - 0.45 |
|---|
| Volume: | 42,509 |
|---|
| Avg Vol (3m): | 9,406 |
|---|
| Market Cap: | 15.73M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Immunovaccine Announces Financial Results for the Quarter Ended March 31, 2013Marketwired(Thu, May 16)
- Immunovaccine Announces Financial Results for the Quarter Ended March 31, 2013Marketwired(Thu, May 16)
- Immunovaccine Announces Results of 2013 Annual General MeetingMarketwired(Tue, Apr 30)
- Immunovaccine Announces Results of 2013 Annual General MeetingMarketwired(Tue, Apr 30)
- Immunovaccine Receives Financial Contribution from the Government of Canada to Provide Support Towards Clinical Studies in Common Respiratory Illness Affecting Both Children and the ElderlyMarketwired(Tue, Apr 16)
- Immunovaccine Receives Financial Contribution from the Government of Canada to Provide Support Towards Clinical Studies in Common Respiratory Illness Affecting Both Children and the ElderlyMarketwired(Tue, Apr 16)
- Immunovaccine Announces 2012 Year-End ResultsMarketwired(Thu, Mar 28)
- Immunovaccine Announces 2012 Year-End ResultsMarketwired(Thu, Mar 28)
- Immunovaccine Closes Private Placement Financing at $1.6 MillionMarketwired(Tue, Mar 5)
- Immunovaccine Provides Update on Private Placement FinancingMarketwired(Wed, Feb 27)
- IIROC Trading Resumption - IMVCNW Group(Wed, Feb 6)
- Immunovaccine Announces Financing PlansMarketwired(Wed, Feb 6)
- IIROC Trading Halt - IMVCNW Group(Wed, Feb 6)
- Immunovaccine Announces a Proposed Equity OfferingMarketwired(Tue, Feb 5)
- Immunovaccine Signs Agreement for Phase I/II Clinical Trial of DPX-0907 in Breast and Ovarian Cancer PatientsMarketwired(Wed, Jan 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Immunovaccine Inc., a clinical-stage vaccine development company, focuses on the development and advancement of vaccine platform and product candidates for cancer therapy, infectious disease, and animal health.
View More